The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
Pharmaceutical company Sanofi-Aventis Australia has told us that their 2 brands of diltiazem 360 mg controlled-release capsules are being discontinued in Australia due to manufacturing issues.
- Cardizem CD 360 mg became unavailable in June 2026.
- Vasocardol CD 360 mg will no longer be supplied in Australia from 1 November 2026, with reduced supply expected until stock is exhausted.
Controlled-release diltiazem capsules are indicated for the treatment of hypertension. They are also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina.
To help patients have continuous access to this medicine, we have made a Serious Scarcity Substitution Instrument (SSSI) that allows a pharmacist to dispense diltiazem 180 mg controlled-release capsules in place of diltiazem 360 mg controlled-release capsules without a new prescription. The SSSI will be active between 1 October 2026 and 1 October 2027.
For detailed information about the SSSI and important factors when considering a substitution, visit About the discontinuation of diltiazem 360 mg controlled-release capsules.
For more information about SSSIs see Substituting scarce medicines and Serious Scarcity Substitution Instruments (SSSIs).